Structure Therapeutics Inc.

Structure Therapeutics Inc. is a clinical stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral biased small molecule agonist of the glucagon-like-peptide-1 (GLP-1) receptor, which is being evaluated in two phase 2 clinical trials for obesity, overweight, and related conditions. The company also has ACCG-2671 and ACCG-3535, oral small molecule amylin receptor agonists in phase 1 trials for obesity. Additionally, its pipeline includes ANPA-0073, an oral APJ receptor agonist, and LTSE-2578, an antagonist targeting the lysophosphatidic acid 1 receptor, both for idiopathic pulmonary fibrosis. Structure Therapeutics is also developing programs for glucose-dependent insulinotropic polypeptide receptor (GIPR) modulation and GCG receptor (GCGR) modulation, including dual agonists, for potential treatments in obesity.

Structure Therapeutics Inc. is listed on the NasdaqGM exchange under the ticker symbol GPCR. Its securities trade in United States Dollars (USD). The company is headquartered in South San Francisco, California, and operates primarily in the United States.

Structure Therapeutics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical stage biopharmaceutical company, it focuses on researching and developing novel oral small molecule therapeutics for chronic diseases, particularly in metabolic and fibrotic conditions.

Structure Therapeutics Inc. is headquartered in South San Francisco, California, United States. The company serves the United States market, as indicated by its country and region designation. It is a global biopharmaceutical company, but its current operations and clinical trials are primarily based in the U.S.

Structure Therapeutics Inc.'s pipeline includes several key product candidates. The lead candidate is GSBR-1290, an oral biased small molecule GLP-1 receptor agonist in phase 2 trials for obesity and overweight. For obesity, it also has ACCG-2671 and ACCG-3535, oral small molecule amylin receptor agonists in phase 1. For idiopathic pulmonary fibrosis, the company is developing ANPA-0073, an oral APJ receptor agonist, and LTSE-2578, an LPA1 receptor antagonist. Additionally, Structure Therapeutics has early-stage programs targeting GIPR modulation (including dual GLP-1R/GIPR agonists) and GCGR modulation (including dual GLP-1R/GCGR agonists), all aimed at treating obesity and related metabolic conditions.